GBT Global Blood Therapeutics, Inc. Stock Quote

GBT [NASD]

Index	-	P/E	-	EPS (ttm)	-4.04	Insider Own	1.70%	Shs Outstand	61.85M	Perf Week	0.10%
Market Cap	2.56B	Forward P/E	-	EPS next Y	-2.14	Insider Trans	0.00%	Shs Float	54.84M	Perf Month	-7.84%
Income	-247.60M	PEG	-	EPS next Q	-1.01	Inst Own	-	Short Float	20.93%	Perf Quarter	-18.00%
Sales	123.80M	P/S	20.71	EPS this Y	11.80%	Inst Trans	0.51%	Short Ratio	11.77	Perf Half Y	-33.64%
Book/sh	6.73	P/B	6.06	EPS next Y	43.20%	ROA	-34.40%	Target Price	-	Perf Year	-39.67%
Cash/sh	8.93	P/C	4.57	EPS next 5Y	37.00%	ROE	-52.30%	52W Range	36.49 - 83.69	Perf YTD	-5.77%
Dividend	-	P/FCF	-	EPS past 5Y	-0.50%	ROI	-43.00%	52W High	-51.24%	Beta	1.09
Dividend %	-	Quick Ratio	7.50	Sales past 5Y	-	Gross Margin	98.40%	52W Low	11.84%	ATR	1.97
Employees	389	Current Ratio	8.00	Sales Q/Q	1859.00%	Oper. Margin	-	RSI (14)	44.33	Volatility	3.93% 4.59%
Optionable	Yes	Debt/Eq	0.36	EPS Q/Q	37.10%	Profit Margin	-	Rel Volume	0.65	Prev Close	41.33
Shortable	Yes	LT Debt/Eq	0.36	Earnings	Feb 24 AMC	Payout	-	Avg Volume	975.33K	Price	40.81
Recom	2.00	SMA20	-1.61%	SMA50	-7.63%	SMA200	-22.30%	Volume	636,792	Change	-1.26%

Apr-14-21

Initiated

SVB Leerink

Outperform

$54

Mar-12-21

Initiated

Wolfe Research

Outperform

$67

Feb-25-21

Downgrade

William Blair

Outperform → Mkt Perform

Jan-20-21

Downgrade

Piper Sandler

Overweight → Neutral

$75 → $50

Dec-15-20

Resumed

H.C. Wainwright

Buy

$75

Dec-03-20

Initiated

RBC Capital Mkts

Outperform

$75

Nov-06-20

Downgrade

Raymond James

Outperform → Mkt Perform

Oct-06-20

Initiated

Evercore ISI

Outperform

$102

Aug-25-20

Initiated

Raymond James

Outperform

$115

Jul-20-20

Initiated

ROTH Capital

Buy

$129

Jul-13-20

Initiated

BofA Securities

Buy

$92

Jul-01-20

Upgrade

Goldman

Neutral → Buy

$91 → $103

Apr-28-20

Initiated

Stifel

Buy

$112

Jan-31-20

Downgrade

SunTrust

Buy → Hold

$110 → $75

Nov-25-19

Resumed

Cantor Fitzgerald

Overweight

$110 → $98

Nov-06-19

Initiated

Canaccord Genuity

Hold

$50

May-29-19

Resumed

Goldman

Neutral

Dec-03-18

Reiterated

H.C. Wainwright

Buy

$125 → $150

Aug-06-18

Initiated

Piper Jaffray

Overweight

$80

Jun-27-18

Reiterated

H.C. Wainwright

Buy

$73 → $125

Apr-09-21 03:28AM	Shareholders Are Thrilled That The Global Blood Therapeutics (NASDAQ:GBT) Share Price Increased 101% Simply Wall St.
Apr-08-21 07:20AM	Global Blood Therapeutics' Sickle Cell Med Results In Rapid, Durable Improvements In Hemoglobin Levels Throughout 72 Weeks Of Treatment Benzinga
03:00AM	Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients GlobeNewswire
Apr-05-21 08:00AM	GBT Announces New Employment Inducement Grants GlobeNewswire
Apr-04-21 05:18AM	Global Blood Therapeutics: Can This Biotech Still Disrupt The Sickle Cell Disease Space? TipRanks
Mar-26-21 11:30AM	Global Blood (GBT) Down 7.1% Since Last Earnings Report: Can It Rebound? Zacks
Mar-18-21 07:00AM	GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors GlobeNewswire
Mar-16-21 07:00AM	GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A. GlobeNewswire
Mar-08-21 08:00AM	GBT Announces New Employment Inducement Grants GlobeNewswire
Mar-04-21 04:28PM	Top Growth Stocks for March 2021 Investopedia
Mar-02-21 08:00AM	GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease Community GlobeNewswire
07:30AM	GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Feb-25-21 04:01AM	Global Blood Therapeutics (GBT) Q4 2020 Earnings Call Transcript Motley Fool -11.57%
Feb-24-21 04:44PM	Recap: Global Blood Therapeutics Q4 Earnings Benzinga
04:05PM	GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
02:30PM	Global Blood Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-23-21 10:28AM	Preview: Global Blood Therapeutics's Earnings Benzinga
Feb-19-21 08:00AM	GBT Announces Participation in Upcoming Investor Conferences GlobeNewswire
Feb-17-21 08:00AM	GBT to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 GlobeNewswire
Feb-08-21 01:02AM	Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment? Simply Wall St.
Feb-05-21 08:00AM	GBT Announces New Employment Inducement Grants GlobeNewswire
Feb-04-21 08:00AM	GBT Initiates Expanded Access Protocol for Oxbryta® (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United States GlobeNewswire
Jan-28-21 10:12AM	Global Blood's (GBT) MAA for Oxbryta Accepted in Europe Zacks
Jan-27-21 07:00AM	European Medicines Agency Accepts GBTs Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease GlobeNewswire +6.97%
Jan-07-21 08:00AM	GBT Announces New Employment Inducement Grants GlobeNewswire
Jan-06-21 08:13AM	New Strong Sell Stocks for January 6th Zacks
Jan-05-21 08:00AM	GBT Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-25-20 01:54AM	Loss-Making Global Blood Therapeutics, Inc. (NASDAQ:GBT) Expected To Breakeven In The Medium-Term Simply Wall St.
Dec-16-20 10:25AM	RBC: These 3 Stocks Are Poised to Surge by at Least 30% TipRanks -5.04%
Dec-15-20 08:13AM	New Strong Sell Stocks for December 15th Zacks +5.06%
08:00AM	GBT Announces New Employment Inducement Grants GlobeNewswire
Dec-07-20 08:00AM	GBT Appoints Kim Smith-Whitley, M.D., to Lead Research and Development GlobeNewswire -5.70%
Dec-06-20 10:00AM	GBT Presents New Data on the Long-Term and Real-World Use of Oxbryta® (voxelotor) Tablets in Patients with Sickle Cell Disease at 62nd ASH Annual Meeting and Exposition GlobeNewswire
10:00AM	GBT Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential Inclacumab and GBT021601 GlobeNewswire
Dec-05-20 11:32AM	Why Is Global Blood (GBT) Down 27.3% Since Last Earnings Report? Zacks
Dec-03-20 09:56AM	Benzinga's Top Upgrades, Downgrades For December 3, 2020 Benzinga
Dec-02-20 07:00AM	GBT Initiates Early Access Program for Voxelotor in Patients with Sickle Cell Disease in Europe and Other Regions Outside the United States GlobeNewswire -7.06%
Nov-25-20 08:00AM	GBT Announces Participation in Upcoming Investor Conferences GlobeNewswire
Nov-13-20 08:45AM	Global Blood Therapeutics (GBT) Surges: Stock Moves 6.9% Higher Zacks +7.16%
08:00AM	GBT Announces Participation at the Stifel 2020 Virtual Healthcare Conference GlobeNewswire
Nov-10-20 06:04AM	Analysts Just Slashed Their Global Blood Therapeutics, Inc. (NASDAQ:GBT) EPS Numbers Simply Wall St.
Nov-09-20 08:00AM	GBT Announces New Employment Inducement Grants GlobeNewswire
Nov-07-20 09:38AM	Global Blood Therapeutics, Inc. (NASDAQ:GBT) Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St.
Nov-06-20 12:13PM	Global Blood Therapeutics Off on Results Miss, Analyst Rating Cut TheStreet.com -36.65%
10:54AM	Global Blood (GBT) Q3 Loss Wider Than Expected, Sales Miss Zacks
Nov-05-20 06:25PM	Global Blood Therapeutics (GBT) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:05PM	GBT Reports Recent Business Progress and Third Quarter 2020 Financial Results GlobeNewswire
02:30PM	Global Blood Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-04-20 03:11PM	GBT Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition GlobeNewswire +14.61%
Nov-02-20 08:11AM	Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares? Simply Wall St.
Oct-29-20 08:00AM	GBT to Announce Third Quarter 2020 Financial Results on Thursday, November 5, 2020 GlobeNewswire
Oct-26-20 06:00AM	GBT Presents Data at 15th Annual Scientific Conference on Sickle Cell and Thalassemia GlobeNewswire
Oct-12-20 08:00AM	GBT Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for Development of Oxbryta® (voxelotor) Tablets GlobeNewswire -6.14%
Oct-05-20 08:00AM	GBT Announces New Employment Inducement Grants GlobeNewswire +8.40%
Sep-18-20 11:31AM	Wells Fargo: These 2 Stocks Could Deliver Triple-Digit Wins TipRanks
Sep-17-20 09:48AM	Announcing: Global Blood Therapeutics (NASDAQ:GBT) Stock Increased An Energizing 102% In The Last Three Years Simply Wall St.
Sep-15-20 12:43AM	Hedge Funds Have Never Been This Bullish On Global Blood Therapeutics Inc (GBT) Insider Monkey
Sep-09-20 08:00AM	GBT and Sickle Cell Disease Association of America to Host 9th Annual Sickle Cell Disease (SCD) Therapeutics Conference GlobeNewswire
Sep-08-20 04:05PM	GBT and Biopharma-MEA Enter Agreement to Distribute Oxbryta® (voxelotor) in Six Middle Eastern Countries GlobeNewswire
Sep-04-20 11:31AM	Why Is Global Blood (GBT) Down 5.6% Since Last Earnings Report? Zacks
08:00AM	GBT Announces New Employment Inducement Grants GlobeNewswire
Sep-03-20 08:00AM	GBT Announces Participation in Upcoming Investor Conferences GlobeNewswire
Aug-26-20 10:44PM	5 Biotech Stocks That Could Be Worth a Look Barrons.com
Aug-25-20 11:39AM	Why Global Blood Therapeutics Is Trading Higher Today Benzinga
09:35AM	Benzinga's Top Upgrades, Downgrades For August 25, 2020 Benzinga
Aug-07-20 08:00AM	GBT Announces New Employment Inducement Grants GlobeNewswire
Aug-05-20 05:35PM	Global Blood Therapeutics (GBT) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	GBT Reports Recent Business Progress and Second Quarter 2020 Financial Results GlobeNewswire
Aug-03-20 12:54PM	Is Global Blood Therapeutics (NASDAQ:GBT) Using Debt In A Risky Way? Simply Wall St.
Jul-30-20 08:00AM	GBT Announces Participation in Upcoming Investor Conferences GlobeNewswire
Jul-29-20 08:00AM	GBT to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 GlobeNewswire
Jul-25-20 09:10AM	3 Top Biotech Stocks to Buy Now Motley Fool
Jul-17-20 12:45PM	Did Hedge Funds Make The Right Call On Global Blood Therapeutics Inc (GBT) ? Insider Monkey
Jul-08-20 08:00AM	GBT Announces New Employment Inducement Grants GlobeNewswire
Jun-25-20 01:00PM	GBT Awards $250,000 in ACCEL Grants to Advance Access to Care for People Living with Sickle Cell Disease GlobeNewswire
08:59AM	Global Blood to Seek Approval of Oxbryta in Europe for SCD Zacks
Jun-24-20 08:30AM	GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (voxelotor) to Treat Sickle Cell Patients in Europe GlobeNewswire
Jun-19-20 01:18AM	Global Blood Therapeutics Inc (GBT): Hedge Funds In Wait-and-See Mode Insider Monkey +5.22%
Jun-18-20 04:05PM	miRagen Strengthens Leadership Team with Appointment of Lee Rauch as Chief Operating Officer GlobeNewswire
09:48AM	Global Blood Therapeutics, Inc. (NASDAQ:GBT): When Will It Breakeven? Simply Wall St.
Jun-12-20 06:37PM	Stocks With Rising Relative Price Strength: Global Blood Therapeutic Investor's Business Daily
Jun-09-20 10:13AM	Global Blood Seeks Label Expansion of Oxbryta in Kids With SCD Zacks
02:08AM	Global Blood Therapeutics Up On Expanded Use Plans For Sickle Cell Treatment SmarterAnalyst
Jun-08-20 04:05PM	GBT Announces Plans to Seek Expanded Labeling for Oxbryta® (voxelotor) to Treat Children Ages 4 to 11 Years with Sickle Cell Disease GlobeNewswire
Jun-05-20 11:31AM	Global Blood (GBT) Down 16.3% Since Last Earnings Report: Can It Rebound? Zacks
Jun-03-20 08:00AM	GBT Announces New Employment Inducement Grants GlobeNewswire
Jun-02-20 10:21PM	Edited Transcript of GBT earnings conference call or presentation 6-May-20 8:30pm GMT Thomson Reuters StreetEvents
08:00AM	GBT Announces Participation at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast GlobeNewswire
May-29-20 06:45AM	Is Global Blood Therapeutics a Buy? Motley Fool
May-24-20 12:25PM	3 Top Pharma Stocks to Buy Right Now Motley Fool
May-15-20 10:58AM	How Global Blood Therapeutics (GBT) Stock Stands Out in a Strong Industry Zacks
May-14-20 09:05AM	GBT Announces Upcoming Data Presentations During Virtual Edition of 25th Annual European Hematology Association Congress GlobeNewswire
May-07-20 08:00AM	GBT Announces New Employment Inducement Grants GlobeNewswire -5.35%
05:48AM	Global Blood Therapeutics Reports Q1 Beat, Impressive Oxbryta Sales SmarterAnalyst
May-06-20 05:35PM	Global Blood Therapeutics (GBT) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	GBT Reports Recent Business Progress and First Quarter 2020 Financial Results GlobeNewswire
May-05-20 08:45AM	Should You Global Blood (GBT) Ahead of Earnings? Zacks
May-04-20 09:10AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Global Blood Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
08:55AM	Should You Buy Global Blood Therapeutics Before This Week's Earnings? Motley Fool
Apr-29-20 08:00AM	GBT to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020 GlobeNewswire

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fink Eric	Chief Human Resources Officer	Oct 05	Sale	60.00	4,532	271,920	0	Oct 07 05:12 PM
PIERCE GLENN	Director	Sep 10	Option Exercise	15.03	15,000	225,450	19,800	Sep 14 06:12 PM
CATHERS BRIAN EDWIN	Chief Scientific Officer	Aug 20	Sale	63.77	2,200	140,294	5,244	Aug 24 05:14 PM
Fink Eric	Chief Human Resources Officer	Aug 05	Sale	69.62	2,454	170,851	0	Aug 07 04:09 PM
Farrow Jeffrey S	Chief Financial Officer	Jul 13	Sale	75.00	15,208	1,140,600	3,048	Jul 15 05:11 PM
Svoronos Dawn	Director	Jun 19	Sale	63.94	2,544	162,663	2,256	Jun 19 09:31 PM
Farrow Jeffrey S	Chief Financial Officer	Jun 09	Sale	67.00	15,208	1,018,936	18,256	Jun 11 04:06 PM
Calhoun Lesley Ann	See Remarks	May 26	Option Exercise	29.75	2,700	80,325	2,854	May 28 04:05 PM
Calhoun Lesley Ann	See Remarks	May 26	Sale	70.10	2,700	189,270	154	May 28 04:05 PM
Calhoun Lesley Ann	See Remarks	May 18	Option Exercise	22.00	23,330	513,260	23,484	May 20 04:07 PM
Calhoun Lesley Ann	See Remarks	May 18	Sale	74.67	23,330	1,742,051	154	May 20 04:07 PM
PERRY MARK L	Director	May 12	Option Exercise	22.04	53,600	1,181,500	80,028	May 13 06:07 PM
Calhoun Lesley Ann	See Remarks	May 12	Sale	78.38	2,992	234,512	154	May 13 06:08 PM
PERRY MARK L	Director	May 12	Sale	78.10	53,600	4,186,061	26,428	May 13 06:07 PM
Calhoun Lesley Ann	See Remarks	May 11	Sale	77.05	381	29,356	3,146	May 13 06:08 PM
LOVE TED W	See Remarks	Apr 28	Sale	80.00	40,000	3,200,160	1,034,633	Apr 29 04:17 PM
LOVE TED W	See Remarks	Apr 27	Sale	80.87	2,817	227,814	1,074,633	Apr 29 04:17 PM
SUVARI TRICIA BORGA	Chief Legal Officer	Apr 20	Sale	75.00	4,080	306,000	7,441	Apr 22 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience